NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCT2051210045

Registered date:02/07/2021

ONO-7475-03 : ONO-7475 Phase 1 Study

Basic Information

Recruitment status Not Recruiting
Health condition(s) or Problem(s) studiedEGFR mutated, stage IIIB/IIIC/IV or recurrent, NSCLC, which is unsuitable for radical irradiation
Date of first enrollment06/08/2021
Target sample size75
Countries of recruitment
Study typeInterventional
Intervention(s)Administration of ONO-7475 with Osimertinib

Outcome(s)

Primary OutcomeTolerability, safety
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum>= 20age old
Age maximumNot applicable
GenderBoth
Include criteria1. Patients with stage IIIB/IIIC/IV or recurrent NSCLC, which is unsuitable for radical irradiation 2. Patients with confirmed EGFR gene exon 19 deletion or EGFR gene exon 21 mutation(L858R)and who are scheduled to receive osimertinib 3. Patient has an ECOG performance status of 0-1
Exclude criteria1. Patients with severe complication 2. Patients with multiple primary cancers

Related Information

Contact

Public contact
Name Medical Information Center
Address 3 -1 -1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan Osaka Japan 618-8585
Telephone +81-120626190
E-mail clinical_trial@ono-pharma.com
Affiliation Ono Pharmaceutical Co.,LTD
Scientific contact
Name Masahiro Osawa
Address 3 -1 -1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan Osaka Japan 618-8585
Telephone +81-120626190
E-mail clinical_trial@ono-pharma.com
Affiliation Ono Pharmaceutical Co.,LTD